Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Instructions to Decide the Best SUV Size for Seniors - 2The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- 3Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 4Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 5World's oldest known tortoise still very much alive despite rumor to the contrary
- 10 Demonstrated Systems to Develop Your Internet based Business
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- 5 VIP Voice Exhibitions in Energized Movies
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
- The Best Games On the planet
- Day to day Temporary Positions That Compensate Fairly in the US
- Coca-Cola Co. and bottlers to invest in South Africa operations
